AI, Cybersecurity & Catastrophic Dual-Use Risk

The strongest good-faith objection: mandatory gene-synthesis screening applied uniformly to every commercial provider imposes disproportionate cost on smaller providers relative to the marginal risk any one of them individually presents, and could push the industry toward consolidation around a handful of large incumbents able to absorb the compliance burden: an unintended market-concentration effect this issue's proposal doesn't fully work through. A critic could argue a risk-tiered or size-adjusted requirement would better balance the catastrophic-risk goal against this concentration side effect. That's a design parameter worth getting right, not a reason to leave the largest gap — voluntary, funding-conditional screening — in place. A requirement scaled to a provider's synthesis volume and capability, rather than identical paperwork for a garage lab and a major biotech firm, addresses the concentration concern directly without touching the part of this position that isn't negotiable: every commercial provider screens for the catastrophic cases, full stop.

A second strong objection applies specifically to the critical-infrastructure early-access proposal: any program that gives some operators and some labs earlier access to powerful capability than everyone else creates exactly the kind of asymmetric arrangement that's historically bred favoritism, regulatory capture, or the appearance of it, whether or not any actual corruption occurs. A critic could argue the safest design has no early-access tier at all. This issue's answer is that the alternative, letting critical infrastructure hardening wait for the same release schedule as the general public, gives attackers and defenders identical timing, which isn't neutral, it favors whoever is faster to weaponize a new capability. The proposal's actual safeguard against favoritism isn't refusing early access, it's making qualification mechanical: published technical criteria, applied identically to every operator and every lab that asks, evaluated the way NIST evaluated post-quantum cryptography submissions, not the way a single agency's discretionary waiver would work. A program that can't clear that bar shouldn't launch; one that can isn't the same thing as a backroom deal.

Smaller biotech and gene-synthesis providers bear disproportionate compliance cost relative to large incumbents. The public bears residual risk if screening has gaps or if providers operate offshore, outside the mandate's practical reach. Legitimate researchers doing dual-use work bear friction and delay from screening and reporting requirements, a cost this issue accepts as the price of closing a gap it considers more dangerous to leave open. Smaller critical-infrastructure operators and smaller frontier labs bear the cost of meeting the same published qualification bar as larger, better-resourced incumbents in the early-access program; the public bears the residual risk of a flawed vetting process if that bar is ever weakened case by case rather than enforced uniformly.